Previous 10 | Next 10 |
2023-05-14 13:55:03 ET Ventyx Biosciences, Inc. (VTYX) Q1 2023 Earnings Conference Call May 11, 2023 04.30 PM ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chief M...
2023-05-11 16:14:02 ET Ventyx Biosciences press release ( NASDAQ: VTYX ): Q1 GAAP EPS of -$0.68 misses by $0.03 . For further details see: Ventyx Biosciences GAAP EPS of -$0.68 misses by $0.03
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is progressing, with topline data expe...
ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today anno...
ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, tod...
2023-03-23 20:41:06 ET Ventyx Biosciences, Inc. (VTYX) Q4 2022 Earnings Conference Call March 24, 2023 04:30 p.m. ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chi...
2023-03-23 16:04:02 ET Ventyx Biosciences press release ( NASDAQ: VTYX ): Q4 GAAP EPS of -$0.62 beats by $0.02 . Cash, cash equivalents and marketable securities of $356.6 million at the end of 2022 plus an additional $48.4 million in net proceeds raised in Q1 2023 und...
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis (UC) is on track to complete e...
2023-03-21 09:28:28 ET Ventyx Biosciences ( NASDAQ: VTYX ) traded higher pre-market Tuesday after Wells Fargo initiated its coverage with an Overweight recommendation citing an attractive entry point ahead of multiple catalysts over the next 12 – 18 months. The comp...
2023-03-20 08:57:38 ET Summary Dan Loeb's 13F portfolio value increased from $5.53B to $5.97B this quarter. The number of positions decreased from 61 to 44. Third Point added American International Group, Microsoft, and International Flavors & Fragrances while dropping Cano He...
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Ventyx Biosciences Inc. Website:
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semag...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...